Optimal allocation strategies for HPV vaccination introduction and expansion in China accommodated to different supply and dose schedule scenarios: a modelling study

You, Tingting; Zhao, Xuelian; Hu, Shangying; Gao, Meng; Liu, Yang; Zhang, Yong; Qiao, You‐Lin; Jit, Mark; Zhao, Fen

doi:10.1016/j.eclinm.2022.101789

Cited by 11 publications

(15 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three recent modelling studies have examined the potential population-level effectiveness of one-dose HPV vaccination in LMICs. 29 , 30 , 31 First, a comparative modelling study 29 that we did with colleagues from Harvard University, found that early implementation of one-dose routine vaccination of girls in Uganda would lead to greater health benefits than waiting 5 years until more information on vaccine efficacy is available from ongoing trials. The conclusion was robust across a range of revaccination mitigation scenarios.…”

Section: Discussionmentioning

confidence: 99%

“…The conclusion was robust across a range of revaccination mitigation scenarios. Second, a modelling study 30 projecting the potential effectiveness of HPV vaccination in China showed that one-dose vaccination of girls aged 14 years could avert 81–98% of the cervical cancers that would be averted with two-dose vaccination over 100 years (assuming 85% vaccine efficacy). Finally, a modelling study 31 from IARC projected that one-dose vaccination of girls aged 10 years in India could reduce the lifetime risk of cervical cancer by 71–78% (depending on vaccine efficacy assumptions) and would be an efficient use of HPV vaccine doses.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis

Bénard,

Drolet,

Laprise

et al. 2023

The Lancet Public Health

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis

Bénard,

Drolet,

Laprise

et al. 2023

The Lancet Public Health

View full text Add to dashboard Cite

“…Another bivalent HPV (types 16 and 18) vaccine was licenced in 2022. Known as Walrinvax, the vaccine was produced in Pichia pastoris by Walvax and GSK 88 …”

Section: Virus‐like Particles For Vaccine Developmentmentioning

confidence: 99%

Virus‐like particles as powerful vaccination strategy against human viruses

Hadj Hassine,

Ben M'hadheb,

Almalki

et al. 2023

Reviews in Medical Virology

View full text Add to dashboard Cite

Nowadays, viruses are not only seen as causative agents of viral infectious diseases but also as valuable research materials for various biomedical purposes, including recombinant protein production. When expressed in living or cell‐free expression systems, viral structural proteins self‐assemble into virus‐like particles (VLPs). Mimicking the native form and size of viruses and lacking the genetic material, VLPs are safe and highly immunogenic and thus can be exploited to develop antiviral vaccines. Some vaccines based on VLPs against various infectious pathogens have already been licenced for human use and are available in the commercial market, the latest of which is a VLP‐based vaccine to protect against the novel Coronavirus. Despite the success and popularity of VLP subunit vaccines, many more VLPs are still in different stages of design, production, and approval. There are still many challenges that require to be addressed in the future before this surface display system can be widely used as an effective vaccine strategy in combating infectious diseases. In this review, we highlight the use of structural viral proteins to produce VLPs, emphasising their intrinsic properties, structural classification, and main expression host systems. We also compiled the recent scientific literature about VLP‐based vaccines to underline the recent advances in their application as a vaccine strategy for preventing and fighting virulent human pathogens. Finally, we presented the key challenges and possible solutions for VLP‐based vaccine production.

show abstract

“…When introducing HPV vaccine into the national program, all the HPV vaccines are cost-effective in China among the WHO-recommended primary target group of females at 9–14 years with the incremental cost-effectiveness ratio (ICER) less than the gross domestic product (GDP) per capita for 2021 (USD 12,457.85) [assuming a lower tender price than the market price based on the Pan American Health Organization Revolving Fund (PAHO-RF) vaccine price for 2022] [ 17 , 18 ]. Furthermore, the earlier HPV vaccination program is initiated, the greater health and cost benefits will be gained [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, the earlier HPV vaccination program is initiated, the greater health and cost benefits will be gained [ 8 ]. Regarding the HPV vaccine supply and dose restrictions, Chinese scientists reported that 14-year-old girls should be given priority when on-label use of HPV vaccines [ 17 ]. If the one-dose schedule of HPV vaccine recommended by the updated WHO position paper is permitted in China, reallocating the second dose from the routine cohorts to add a catch-up vaccination at 20 years of age would be the most efficient strategy, but more local evidence is needed to support the one-dose HPV vaccination in China [ 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

Tackling barriers to scale up human papillomavirus vaccination in China: progress and the way forward

Zhao,

Hu,

et al. 2023

Infect Dis Poverty

Self Cite

View full text Add to dashboard Cite

The human papillomavirus (HPV) vaccine is the first vaccine developed specifically targeting the prevention of cervical cancer. For more than 15 years, China has expedited a series of efforts on research and development of the domestically manufactured HPV vaccines, producing local population-based evidence, promoting free HPV vaccination from pilots, and launching action plans to tackle barriers in the scale-up of HPV vaccination. To further roll out the HPV vaccination program in China, several challenges should be addressed to support the steps forward. The availability of more locally manufactured HPV vaccines, pricing negotiation and local evidence supporting the efficacy of one-dose schedule would greatly alleviate the continued supply and financial constraints in China. Meanwhile, more attention should be paid to girls living in low-resource areas and males to ensure equal access to the HPV vaccination. Furthermore, linkage to secondary prevention and further real-world monitoring and evaluation are warranted to inform effective cervical cancer prevention strategies in the post-vaccine era. Graphical Abstract

show abstract

Optimal allocation strategies for HPV vaccination introduction and expansion in China accommodated to different supply and dose schedule scenarios: a modelling study

Cited by 11 publications

References 24 publications

Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis

Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis

Virus‐like particles as powerful vaccination strategy against human viruses

Tackling barriers to scale up human papillomavirus vaccination in China: progress and the way forward

Contact Info

Product

Resources

About